Loading...
Loading...
Curative Biotechnology Inc
Curative Biotechnology Inc. Spoken Alpha tracks CUBT's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks CUBT's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CUBT.
curl https://api.spokenalpha.com/v1/companies/CUBT| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $5.27 | $4.07 | +29.5% | -3.4% | -1.7% |
| Q4 FY2026 | $6.07 | $4.24 | +43.2% | +4.0% | +4.5% |
| Q3 FY2026 | $5.76 | $4.25 | +35.5% | +2.8% | +0.6% |
| Q2 FY2026 | $5.52 | $4.24 | +30.1% | +5.3% | +3.8% |
| Q1 FY2025 | $6.22 | $4.31 | +44.3% | -2.6% | -0.3% |
| Q4 FY2025 | $6.15 | $4.39 | +40.0% | +6.6% | +6.8% |
| Q3 FY2025 | $5.99 | $4.17 | +43.7% | -0.8% | -1.7% |
| Q2 FY2025 | $6.08 | $4.42 | +37.5% | 0.0% | -1.4% |
| Q1 FY2024 | $6.19 | $4.38 | +41.3% | +4.5% | +3.4% |
| Q4 FY2024 | $5.44 | $4.18 | +30.2% | -1.9% | -1.7% |